Angiogenesis and current antiangiogenic strategies for the treatment of cancer.
Angiogenesis is a complex process critical for embryonic development and for survival. It is also a critical player in many pathologic processes, most notably in neoplasia. The cell signaling pathways involved in angiogenesis have become key targets for drug design, with more than 2,500 clinical trials currently under way. This review summarizes the essential features of angiogenesis and discusses therapeutic strategies that have been applied to specific diseases known to be associated with perturbation of normal angiogenic control.
Oklu
Rahmi
R
Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114-2696, USA. r6251@yahoo.com
Walker
Thomas G
TG
Wicky
Stephan
S
Hesketh
Robin
R
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D006801:Humans; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000503:physiopathology / Q000517:prevention & control*; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D018570:Risk Assessment; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors